University of Southern California
USC Norris Comprehensive Cancer Center

Not logged in...

If you are a patient, please contact Keck Medical Center of USC at 800-USC-CARE.

Trial 2N-17-1

PhII-156 A Phase II trial of AZD9291 (osimertinib) with or without bevacizumab in patients with EGFR mutation positive NSCLC and brain metastases

Type: Treatment
Phase: Phase II
Status: Open to Accrual
Treatments: Anti-Angiogenesis, Biological Response Modifier
Randomized: Yes
Defintions of terms and FAQ about clinical trials.
Trial Leaders/Researchers:  Bing Xia, M.D.
Other Trial Staff:  Ramona Lujan, Coordinator, Aaron Mejia, D.M., Grace Facio, Coordinator, Charlean Ketchens, Coordinator, Gina Tse, Coordinator, Shamim Jhimlee, Coordinator, Yanli Wang, D.M., Bartolo Santos, Coordinator, Peter Alexander, Coordinator

Staff may log in to see study documents.

Click here to see trial eligibility criteria and further details at

For further information on a study, please contact the Clinical Investigation Support Office at (323) 865-0451, or

To schedule a consultation with the hospital, please call our New Patient Referrals Office at (323) 865-3111.